Key result
CBR3 polymorphisms and BNP levels are linked to doxorubicin-induced cardiotoxicity in breast cancer.
Why the study?
Doxorubicin causes cardiotoxicity via CBR3-catalyzed metabolites and ABCC1 accumulation, prompting investigation into whether CBR3 and ABCC1 genetic polymorphisms affect cardiotoxicity and whether BNP serves as an early biomarker in breast cancer patients.
Do CBR3 and ABCC1 genetic polymorphisms and BNP levels predict doxorubicin-induced cardiotoxicity in breast cancer patients?
Cohort (n=100)
Do CBR3 and ABCC1 genetic polymorphisms and BNP levels predict doxorubicin-induced cardiotoxicity in breast cancer patients?
p-value: p=0.023
Detecting CBR3 genetic polymorphisms and monitoring BNP levels may aid in the early detection and risk assessment of doxorubicin-induced cardiotoxicity in breast cancer patients.
BACKGROUND: Doxorubicin (DOX), a potent antineoplastic drug, can induce cardiotoxicity through its cardiotoxic metabolites catalyzed by CBR 3 and its accumulation in cardiac tissue via the ABCC1 transporter. Here, we investigated CBR3 and ABCC1 genetic polymorphisms affecting doxorubicin cardiotoxicity in breast cancer patients and explored the potential role of brain natriuretic peptide (BNP) as an early cardiac biomarker. METHODS: One hundred Breast cancer patients are receiving DOX treatment. Blood samples were analyzed for CBR3 and ABCC1 gene polymorphisms and echocardiography and BNP biomarkers were used to assess cardiotoxicity at baseline and three months post-DOX treatment. RESULTS: = 0.023). CONCLUSION: Detecting CBR3 genetic polymorphisms is crucial for assessing cardiotoxicity before administering DOX, and monitoring BNP levels helps early detection. CBR3 is also associated with DOX anemia.
No takes yet. Share an insight, caveat, or question.
El-Shorbagy et al. (2025) conducted a cohort in Breast cancer (n=100). CBR3 and ABCC1 genetic polymorphisms was evaluated on Cardiotoxicity assessed by echocardiography and BNP biomarkers (p=0.023). CBR3 genetic polymorphisms and BNP levels were associated with doxorubicin-induced cardiotoxicity in breast cancer patients (P=0.023).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: